Max P. Kristiansen

Max P. Kristiansen

Auto-generated profile, based on publicly available information

Max P. Kristiansen

Center for Vaccine Research, Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
SJSynne Jenum
Synne Jenum
KTKristian Tonby
Kristian Tonby
CRCorina S. Rueegg
Corina S. Rueegg
MRMorten Rühwald
Morten Rühwald
MKMax P. Kristiansen
Max P. Kristiansen
ARAnne Margarita Dyrhol Riise
Anne Margarita Dyrhol Riise
Host-directed-therapy strategies are warranted to fight tuberculosis. Here we assess the safety and immunogenicity of adjunctive vaccination with the H56:IC31 candidate and cyclooxygenase-2-inhibitor treatment (etoricoxib) in pulmonary and extra-pulmonary tuberculosis patients in a randomized open-label phase I/II clinical trial (TBCOX2, NCT02503839). A total of 222 patients were screened, 51 enrolled and randomized; 13 in the etoricoxib-group, 14 in the H56:IC31-group, 12 in the etoricoxib+H56:IC31-group and 12 controls. Three Serious Adverse Events were reported in the etoricoxib-groups; two urticarial rash and one possible disease progression, no Serious Adverse Events were vaccine related. H56:IC31 induces robust expansion of antigen-specific T-cells analyzed by fluorospot and flow cytometry, and higher proportion of seroconversions. Etoricoxib reduced H56:IC31-induced T-cell responses. Here, we show the first clinical data that H56:IC31 vaccination is safe and immunogenic in tuberculosis patients, supporting further studies of H56:IC31 as a host-directed-therapy strategy. Although etoricoxib appears safe, our data do not support therapy with adjunctive cyclooxygenase-2-inhibitors.

23 February 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
AOAnja W. Olsen
Anja W. Olsen
IRIda Rosenkrands
Ida Rosenkrands
CJChristina S. Jacobsen
Christina S. Jacobsen
HCHannah M Cheeseman
Hannah M Cheeseman
MKMax P. Kristiansen
Max P. Kristiansen
FFFrank Follmann
Frank Follmann
The clinical development of an effective Chlamydia vaccine requires in-depth understanding of how well protective pre-clinical immune signatures translate to humans. Here, we report a comparative immunological characterization of CTH522/CAF®01 in female mice and humans. We find a range of immune signatures that translate from mouse to human, including a Th1/Th17 cytokine profile and antibody functionality. We identify vaccine-induced T cell epitopes, conserved among Chlamydia serovars, and previously found in infected individuals. Using the mouse model, we show that the common immune signature protected against ascending infection in mice, and vaccine induced antibodies could delay bacterial ascension to the oviduct, as well as development of pathology, in a T cell depleted mouse model. Finally, we demonstrate long-lasting immunity and protection of mice one year after vaccination. Based on the results obtained in the present study, we propose to further investigate CTH522/CAF®01 in a phase IIb study.

6 July 2023 in Research Square
Verified
Preprint
Open access
PDF file
AOAnja Olsen
Anja Olsen
IRIda Rosenkrands
Ida Rosenkrands
CJChristina Jacobsen
Christina Jacobsen
HCHannah Cheeseman
Hannah Cheeseman
MKMax Kristiansen
Max Kristiansen
FFFrank Follmann
Frank Follmann
The clinical development of an effective Chlamydia vaccine requires in-depth understanding of how well protective pre-clinical immune signatures translate to humans. Here we report the first comparative immunological characterization of CTH522/CAF®01 in mice and humans. We find a range of immune signatures that translate from mouse to humans, including a Th1/Th17 cytokine profile and antibody functionality. Interestingly, we identified vaccine-induced T cell epitopes, conserved among serovars and previously found in infected individuals. Using the mouse model, we show that the common immune signature protected against ascending infection in mice and vaccine induced antibodies could delay bacterial ascension to the oviduct, as well as development of pathology, in a T cell depleted mouse model. Finally, we demonstrate long-lasting immunity and protection of mice one year after vaccination. Based on the results obtained in the present study, we propose to further investigate CTH522/CAF®01 in a phase IIb study.